LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・MacroGenics Inc
Search

MacroGenics Inc

Chiusa

SettoreSettore sanitario

3.88 -0.51

Acquista

Aggiornamento del prezzo 10 giu 2026, 19:59 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.82

Massimo

4.03

Metriche Chiave

By Trading Economics

Entrata

-23M

-37M

Vendite

-20M

21M

EPS

-0.58

Margine di Profitto

-177.011

Dipendenti

293

EBITDA

-17M

-32M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+63.57% upside

Dividendi

By Dow Jones

Utili prossimi

12 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

59M

247M

Apertura precedente

4.39

Chiusura precedente

3.88

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 344 Classifica in Healthcare

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2026, 23:36 UTC

Utili

Correction to Oracle Reports Higher 4Q Profit Article

DJ

LeggI

10 giu 2026, 23:19 UTC

Azioni calde

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

LeggI

10 giu 2026, 23:09 UTC

I principali Market Mover

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

LeggI

10 giu 2026, 23:04 UTC

Utili

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

LeggI

10 giu 2026, 20:44 UTC

I principali Market Mover

Caterpillar Raises Quarterly Dividend 8%

DJ

LeggI

10 giu 2026, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

LeggI

10 giu 2026, 23:47 UTC

Discorsi di Mercato

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

LeggI

10 giu 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

LeggI

10 giu 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

LeggI

10 giu 2026, 23:32 UTC

Discorsi di Mercato

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

LeggI

10 giu 2026, 23:20 UTC

Discorsi di Mercato

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

LeggI

10 giu 2026, 22:05 UTC

Discorsi di Mercato

Correction to Bank of Canada Stays on Hold Market Talk

DJ

LeggI

10 giu 2026, 21:57 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:52 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:35 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:22 UTC

Utili

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:39 UTC

Discorsi di Mercato
Utili

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

LeggI

10 giu 2026, 20:34 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Utili

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

LeggI

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

63.57% in crescita

Previsioni per 12 mesi

Media 6.33 USD  63.57%

Alto 9 USD

Basso 4 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

154 / 344 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Altri titoli del settore

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat